A pilot randomized controlled trial comparing noradrenaline and adrenaline as a first-line vasopressor for fluid-refractory septic shock in neonates

dc.contributor.authorReema Garegrat1 ,
dc.contributor.authorSuprabha Patnaik
dc.contributor.authorSonali Suryawanshi
dc.contributor.authorChinmay Chetan
dc.contributor.authorNishant Banait
dc.contributor.authorPari Singh
dc.contributor.authorAditya Kallimath
dc.contributor.authorNaharmal B. Soni
dc.contributor.authorYogen Singh
dc.contributor.authorPradeep Suryawanshi
dc.date.accessioned2025-09-27T06:06:13Z
dc.date.issued2024-10-13
dc.description.abstractBackground and study design: Limited data exists on noradrenaline therapy in neonatal septic shock. We compared the efficacy of noradrenaline with adrenaline in neonatal septic shock. This single center, open label, pilot randomized controlled trial included neonates with clinical evidence of sepsis and shock. Study outcomes: Primary outcomes were: 1) resolution of shock one hour after treatment, and 2) mortality during hospital stay. Secondary outcomes included: need for additional vasopressors; hemodynamic stability without further administration of vasopressors for ≥2 h; changes in blood pressure and heart rate after 1 h of vasopressor treatment; and morbidities during the hospital stay. Results: Of 65 eligible neonates, 42 were randomized (21 each in adrenaline and noradrenaline treatment arms) between August 2020 and January 2022, at level III neonatal intensive care unit (NICU) of Bharati Vidyapeeth Deemed University Medical College and Hospital (BVDUMCH). The mean (SD) gestational age and mean (SD) birth weight were 36.1(4.2) weeks and 1.8 (0.2) kilograms birth weight for noradrenaline and 36.9 (4.1) weeks and 1.7 (0.7) kilograms for adrenaline. Shock resolved within 1 h of vasopressor therapy in 76.2% neonates in the noradrenaline arm and 61.9% in adrenaline arm (p value-0.53). Mortality during hospital stay was 28.6% (6/21) in noradrenaline group and 33.3% (7/21) in adrenaline group (p value- 0.58). Additional vasopressors were required in 23.8% neonates of the noradrenaline group compared to 38.1% neonates in adrenaline arm (p value-0.53). Median (SD) duration of intensive care stay was 6 (SD) days in the noradrenaline group and 10 (SD) days in the adrenaline group (p value-0.045). Conclusion: Among neonates with septic shock, the efficacy of noradrenaline was comparable to adrenaline in resolving septic shock after one hour of infusion and on the mortality during hospital stay
dc.identifier.citationGaregrat R, Patnaik S, Suryawanshi S, Chetan C, Banait N, Singh P, Kallimath A, Soni NB, Singh Y and Suryawanshi P (2024) A pilot randomized controlled trial comparing noradrenaline and adrenaline as a first-line vasopressor for fluidrefractory septic shock in neonates. Front. Pediatr. 12:1443990. doi: 10.3389/fped.2024.1443990
dc.identifier.issn2296-2360
dc.identifier.urihttp://10.0.2.71:4000/handle/123456789/281
dc.language.isoen
dc.publisherPUBMED
dc.subjectadrenaline
dc.subjectneonate
dc.subjectnoradrenaline
dc.subjectsepsis
dc.subjectseptic shock
dc.titleA pilot randomized controlled trial comparing noradrenaline and adrenaline as a first-line vasopressor for fluid-refractory septic shock in neonates
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
fped-12-1443990.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description: